H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential

Core Viewpoint - Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is identified as a promising investment opportunity with significant upside potential, driven by its innovative technology and strategic collaborations [1][2]. Group 1: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on developing technologies for the oral administration of biologics and drugs, providing an alternative to painful injections in the US [3]. Group 2: Investment Drivers - H.C. Wainwright analyst Brandon Folkes initiated coverage of Rani Therapeutics with a Buy rating and a price target of $11, highlighting three major value drivers: the RaniPill platform technology, a collaboration with Chugai Pharmaceutical for a hemophilia product, and five additional drug targets including RT-114, an oral GLP-1/GLP-2 dual agonist candidate [1][2]. - Maxim raised its price target on Rani Therapeutics from $5 to $10, also maintaining a Buy rating, following the announcement of the licensing deal with Chugai Pharmaceutical and a private placement to raise $60 million [2]. Group 3: Future Outlook - The upcoming data readouts on RT-114 are expected to be the primary catalyst for near-term value creation for Rani Therapeutics' shares [2].